Integrating hemodynamics identifies an extreme pulmonary hypertension phenotype
Image : https://jnj-content-lab.brightspotcdn.com/dims4/default/7cd336f/2147483647/strip/true/crop/4203x1944+50+1359/resize/1440x666!/quality/90/?url=http%3A%2F%2Fjnj-brightspot.s3.amazonaws.com%2F3f%2F0a%2Fc32edd744c9da614fc84f9d82747%2Fshutterstock-1732953
William M.Â Oldham,Â EdwardÂ Hess,Â Stephen W.Â Waldo,Â MarcÂ Humbert,Â GauravÂ Choudhary,Â Bradley A.Â Maron
European Respiratory JournalÂ 2021;Â DOI:Â 10.1183/13993003.04625-2020
Pulmonary hypertension (PH) is a highly morbid disease defined foremost by elevated mean pulmonary artery pressure (mPAP) measured during right heart catheterisation (RHC) at rest. Patients are classified further into one of three PH hemodynamic subgroups based on specific pulmonary artery wedge pressure (PAWP) and pulmonary vascular resistance (PVR) thresholds: pre-capillary PH (PAWP â‰¤15â€…mmHg+PVR â‰¥3.0â€…WU), isolated post-capillary PH (PAWP >15â€…mmHg+PVR <3.0â€…WU), and combined pre-/post-capillary PH (PAWP >15â€…mmHg+PVR â‰¥3.0â€…WU) .
This manuscript has recently been accepted for publication in theÂ European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theÂ ERJÂ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Oldham has nothing to disclose.
Conflict of interest: Dr. Hess has nothing to disclose.
Conflict of interest: Dr. Waldo reports other from Abiomed , other from Cardiovascular Systems Incorporated , other from Janssen Pharmaceuticals., outside the submitted work; .
Conflict of interest: Dr. Humbert reports personal fees from Actelion, personal fees from Acceleron, personal fees from Bayer , personal fees from Merck, outside the submitted work; .
Conflict of interest: Dr. Choudhary has nothing to disclose.
Conflict of interest: Dr. Maron reports personal fees from Actelion, outside the submitted work; In addition, Dr. Maron has a patent US patent 9,605,047 issued, a patent US pending patent PCT/US2019/059890 pending, a patent provisional patent applications 62475955 pending, and a patent provisional patent applications 029672 pending.
- Copyright Â©The authors 2021. For reproduction rights and permissions contactÂ email@example.com